Table 3.
Variable | HR (95% CI) | p value |
---|---|---|
Age | 1.02 (0.96, 1.08) | 0.51 |
Gender Female: male |
1.24 (0.44, 3.51) | 0.69 |
Race Not Caucasian: Caucasian |
0.88 (0.25, 3.14) | 0.85 |
BMI | 0.91 (0.82, 1.02) | 0.11 |
Smoking status | 0.005 | |
Former: current | 1.53 (0.42, 5.58) | |
Never: current | 21.0 (1.76, 251) | |
Pack years | 0.99 (0.97, 1.01) | 0.38 |
CCI 3-6: CCI 0-2 | 1.28 (0.45, 3.60) | 0.65 |
Tumor size | 1.33 (0.99, 1.78) | 0.050 |
SUV | 0.98 (0.91, 1.07) | 0.66 |
FEV1, % predicted | 1.01 (0.99, 1.03) | 0.37 |
DLCO, % predicted | 0.98 (0.95, 1.02) | 0.38 |
Histology | 0.95 | |
Squamous: adenocarcinoma | 1.08 (0.29, 4.02) | |
Small cell: adenocarcinoma | 1.80 (0.21, 15.6) | |
Clinical stage | 0.093 | |
IB: IA | 1.19 (0.32, 4.45) | |
IIA: IA | 3.93 (1.04, 14.8) | |
KPS | 0.95 (0.91, 1.00) | 0.055 |
Local failure | 1.04 (0.12, 8.77) | 0.97 |
Total dose | 0.98 (0.93, 1.03) | 0.47 |
Fractions | 1.12 (0.83, 1.52) | 0.45 |
Pre-6MWT SBP | 1.00 (0.97, 1.02) | 0.77 |
Pre-6MWT DBP | 0.96 (0.91, 1.01) | 0.15 |
Post-6MWT SBP | 0.98 (0.95, 1.00) | 0.10 |
Post-6MWT DBP | 0.94 (0.90, 0.99) | 0.014 |
Resting HR | 0.98 (0.94, 1.02) | 0.35 |
6MWD | 0.999 (0.997, 1.001) | 0.50 |
6MWD, % pred | 1.00 (0.97, 1.03) | 0.88 |
BDS | 1.33 (1.04, 1.69) | 0.018 |
HR during 6MWT | 0.98 (0.94, 1.01) | 0.19 |
HR-1 min after 6MWT | 1.00 (0.96, 1.03) | 0.85 |
HRR | 1.08 (0.998, 1.16) | 0.054 |
Impaired HRR | 11.0 (1.42, 84.4) | 0.004 |
CI = confidence interval; HR = hazard ratio; 6MWD = 6-minute walk distance; 6MWT = 6-minute walk test; BDS = Borg dyspnea score; BMI = body-mass index; CCI = Charlson comorbidity index; DBP = diastolic blood pressure; DLCO = diffusion capacity of carbon monoxide; FEV1 = forced expiratory volume within 1 second; HR = heart rate; HRR = heart rate recovery; KPS = Karnofsky performance status; LLL = left lower lobe; LUL = left upper lobe; RLL = right lower lobe; RML = right middle lobe; RUL = right upper lobe; SBP = systolic blood pressure; SUV = standardized uptake value